Loss of major histocompatibility Class II expression (MHCII) in diffuse large B-cell lymphoma (DLBCL) correlates with decreased survival. MHCII transcription is in part regulated by histone acetylation. We tested the hypothesis that combination of histone deacetylase inhibitor (HDACI) with standard chemotherapy would improve outcomes in DLBCL in part through increased MHCII expression. S0806 was a single arm phase I/II trial of vorinostat given at 400 mg po daily on days 1-9 (subsequently amended to days 1-5 due to toxicity), combined with R-CHOP given on day 3 of a 21-day cycle for 8 cycles, with primary phase II endpoint of 2-year progression free survival (PFS). With 72 evaluable patients, at median follow up of 3 years, 2-year PFS estimate was 73%, and OS estimate was 86%. Considering that the regimen fell short of predefined efficacy improvement and was associated with high rates of febrile neutropenia (38%) and sepsis (19%), it cannot be recommended for general use. Consistent with our hypothesis, patients with low MCHII expression on S0806 had numerically superior outcomes compared to those from trial S0433 which did not use an HDACI, but the difference was not statistically significant. Current studies are focused on finding biomarkers of response to HDACI. 
| I N TR ODU C TI ON
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma diagnosed in the US, representing 30%-40% of all non-Hodgkin lymphomas.
1 While 55%-60% of patients are cured with R-CHOP, a substantial number of patients relapse and die of their disease. Loss of major histocompatibility Class II antigen (MHCII) expression from the cell surface membrane in DLBCL is associated with a decreased CD81
tumor-infiltrating T-lymphocyte (TIL) response and poor patient survival, independent of international prognostic index (IPI) score or histologic subtype. 2 The negative correlation with outcome is presumably due to the loss of antigen presentation capability on the B cells. In addition, aberrant localization of MHC II protein away from the surface membrane into the cytoplasm, is also associated with shorter progression free survival (PFS), 3, 4 MHCII internalization has been associated with altered ubiquinization, which enhances MHCII endocytosis and localization in late endosomes, and a results in a phenotype similar to immature dendritic cells. 5 Further investigations indicate that deletion of the MHCII gene is infrequent in MHCII surface negative cases, and that altered transcription of the MHCII gene complex is under the control of the master transactivator, CIITA. 6 Activation of CIITA and upregulation of MHCII expression may therefore be a potential therapeutic strategy in DLBCL. The cause of internalized MHCII in B cell lymphomas is unknown, but alteration of the ubiquinization, proteasome, and/or trafficking processes are likely involved.
Epigenetic mechanisms such as DNA hypermethylation or histone deacetylation normally silence gene expression to regulate numerous cellular activities. CIITA is both itself regulated by histone acetylation Therefore, HDACI could potentially enhance MHCII expression. Indeed, in SWOG trial S0520, where another pan-HDACI belinostat was used in the treatment of relapsed/refractory DLBCL, of 2 on-treatment biopsies the one in the responding patient had increased levels of MHCII expression and increased numbers of CD81 T cells, while the one in the nonresponding patient lacked these changes. 10 HDACI have been shown to affect other aspects of the immune system, including regulatory T-cells and cytokines, 11, 12 which may be of clinical relevance.
The phase II study of vorinostat-R-CHOP was thus designed with the hypothesis that the combination of vorinostat with standard chemotherapy would enhance MHCII expression and improve patient outcome in DLBCL, possibly through improving CD81 T cell infiltration and immunosurveillance. The primary endpoint of phase I portion of the trial was to find a safe dose of vorinostat to be used in combination with standard dose of R-CHOP (vincristine capped at 2 mg, prednisone 100 mg flat dose).
| M E TH ODS
Vorinostat starting dose (dose 0) was 400 mg po daily days 1-9, with two preplanned dose de-escalation levels. Dose-limiting toxicity was defined as occurrence of the following in the first cycle of treatment:
grade 3-4 neutropenia or thrombocytopenia lasting more than 7 days; grade 3-4 febrile neutropenia or hemorrhage; grade 3-4 nonhematologic toxicity that persists until cycle 2 day 1; grade 3-4 nausea, vomiting, diarrhea, hypomagnesemia, hypokalemia, hypophosphatemia, or hyperglycemia that persisted despite appropriate management. Ten patients were to be evaluated at the recommended dose prior to proceeding with the Phase II portion of the trial. A temporary closure was to occur prior to opening this study for the Phase II portion in order to assess dose, and to evaluate the safety profile more fully. If 3/10 or fewer patients were have DLT at Dose Level 0, this would be the dose for the Phase II trial. If more than 3/10 patients had DLT at Dose Level 0, enrollment was to stop at this dose after the 4th patient develops DLT and 10 patients were to be enrolled at Dose Level 21.
The primary endpoint of phase II portion was to estimate the two-year PFS, with secondary endpoints of estimating the response rate (complete and partial) and two-year overall survival rate, and of evaluating the toxicity of the vorinostat-R-CHOP combination.
Vorinostat was initially administered at 400 mg po daily days 1 
| Scoring and image analysis
We used an automated image analysis program from Definiens (Cambridge, Massachusetts) version 2.4 for evaluation of staining results of all IHC, with the exception of HLA-DR, which was scored manually since the pattern of staining was of interest (Supporting Information Figure S1 ). Each slide was evaluated for percentage of HLA-DR positive cells, intensity, and pattern of staining (no staining, surface staining, cytoplasmic punctate staining, or mixed surface/punctate), to come up with an HLA-DR score as previously published. 10 Cytoplasmic markers were CD3, CD4, CD8, CD68, and FoxP3; while nuclear markers were acetylated H3 and H4. Detailed methods for automated image analyses are described in Supporting Information Tables S2 and S3. All microscopic evaluations were performed by one of the authors, a hematopathologist (L.R.).
| Serum cytokine analysis
To assess if baseline or changes in serum cytokine levels correlate with PFS (or OS), we collected2 ml of whole blood pretreatment and on day Measurements that were below the lower threshold or above the higher threshold were set as the value of lower threshold or higher threshold respectively.
| Statistical considerations
For Phase I portion of the study, the goal was to establish maximum tolerated dose of vorinostat with standard R-CHOP, with expected accrual of 10-30 patients. A temporary closure would occur prior to opening this study for the Phase II portion in order to assess dose, and to evaluate the safety profile more fully.
For the Phase II portion of study, the primary goal of this portion of the study was to assess the 2-year PFS rate, with secondary endpoints including toxicity, overall survival, and response probability. Sixty-five eligible patients accrued over 18 months with 24 months of additional follow-up would be sufficient to estimate the 2-year PFS within this group to 6 0.13. Sehn et al., 16 found 2-year PFS to be approximately 80% and 60% for patients with intermediate (1-2) and high (3-5) IPI scores, respectively. Given these historical data and assuming that 50%
of accrued patients will be in each IPI risk category, we expected 2-year PFS for R-CHOP to be 70%. Under these assumptions, an estimated 2-year PFS rate of 80% or greater for vorinostat-R-CHOP would be sufficient to warrant further investigation. The target value was to be adjusted based on the observed frequency of prognostic groups. This design had a power of 0.90 and a significance level of 0.05. Assuming 65 eligible patients were accrued to the Phase II portion of this trial, we would be able to estimate the probability of any particular toxicity to within 6 0.13. Any adverse event occurring with at least a 5% probability was likely to be seen at least once (96% chance).
PFS was defined as the time from date of registration to date of first observation of progressive disease or death due to any cause.
Patients last known to be alive and without report of progression are censored at date of last contact. OS was defined as date of registration to date of death due to any cause. Patients last known to be alive are censored at date of last contact. OS and PFS estimates were calculated using the Kaplan-Meier method.
Translational studies included exploratory analyses to assess the association of baseline histone acetylation and T-cell subsets with PFS using univariate Cox regression model. For cytokine analyses, both nominal and Bonferroni adjustments were considered to address multiple comparisons. Additional analyses included patients from a prior SWOG study S0433, and studied the impact of vorinostat-R-CHOP on relative to outcomes on S0433. Comparisons between studies for PFS and OS were assessed by the stratified log-rank test at two-sided alpha level of 0.05.
| RE S U L TS
This study was closed to accrual on October 1, 2013, after meeting its enrollment goal. Data as of July 12, 2016, were included in analyses.
Eighty-three patients were registered.
| Study course
The Phase I portion of this study was activated in four SWOG institutions and was temporarily closed for prespecified analysis with 11 patients registered. One patient was ineligible due to incorrect histology upon hematopathology review, and one patient did not receive any protocol treatment was not analyzable for any endpoint. Of 9 evaluable (10 toxicity-evaluable) phase I patients, two experienced DLTs -grade 3 febrile neutropenia and grade 4 hypokalemia, both in the second week of treatment. Therefore phase II study opened at all centers with vorinostat original starting dose at 400 mg po days 1-9.
As phase I patients completed all treatment and phase II patients started enrollment, excess rates of febrile neutropenia and sepsis were noted, occurring throughout the treatment, from both gram positive and gram negative organisms. Two of phase I patients developed sepsis and one died of it one week after completing all 8 cycles of treatment.
The study was again placed on hold and amended to reduce the duration of vorinostat to 400 mg po days 1-5, to mandate neutrophil growth factor prophylaxis, and to recommend prophylactic antibiotics.
Seventy-two patients were registered on phase II part of the study, of which 2 withdrew consent and did not receive any protocol treatment, and 7 were ineligible (incorrect histology (3), inadequate tissue for diagnosis confirmation (1), nonbulky stage II disease (2), and low platelet count (1)). Sixty-three patients were thus evaluable in phase II part of the trial, for a total of 72 evaluable patients including 9 from the phase I part of the trial. Patient baseline characteristics are outlined in Table 1 . Median age was 64, 92% had stage III/IV disease, 63% had elevated LDH, and 33% had more than one extranodal site involvement, with 58% of patients having IPI 3-5.
| Safety
Five patients in phase I and 29 patients in phase II did not complete all 8 cycles of treatment. Patients received a median of 7 cycles of treatment on protocol. Toxicities are listed in Table 2 . Notable grade 3-4 nonhematologic toxicities included: febrile neutropenia (38%), sepsis (19%), fatigue (17%), hypokalemia (14%), hyponatremia (8%), and small bowel perforation (3%). Grade 3-4 hematologic toxicities included:
neutropenia (63%), anemia (36%), and thrombocytopenia (36%). While there was one death from sepsis and multi-organ failure on phase I as mentioned above, there were no deaths from toxicity in phase II part of the trial.
| Efficacy
As specified in the protocol, clinical primary efficacy analysis was to be based on patients registered to the Phase II component of the study. vs. S0433 revealed numerically superior outcomes in GCB but similar outcomes in non-GCB, again without any statistically significant differences.
Fifty-three evaluable phase I/II patients had MYC expression assessed by IHC, of which 23 were positive; 62 evaluable patients had BCL2 assessment by IHC, of which 40 were positive; of 49 evaluable patients who had both MYC and BCL2 assessment by IHC, 11 (22%) were "double expressor." Patients with "double expressor" DLBCL had similar PFS and OS to patients without MYC/BCL2 overexpression. Despite numerically superior outcomes for "double expressor" lymphoma in S0806 compared to S0433
(2-year PFS 73% vs. 58%, 2-year OS 91% vs. 75%), the differences were not statistically significant. Too few patients had FISH performed locally for MYC and BCL2 to make any conclusions about proportion and outcome of "double-hit lymphoma" on this study.
| Translational studies
HLA-DR was assessed by immunohistochemistry for percent positivity (n 5 58), intensity (n 5 58) and pattern of staining (n 5 52). Forty-six 
HLA-DR score, which takes into account staining positivity by quartile and intensity, as previously published, 10 was not prognostic in S0806 when dichotomized at the median, highest vs. lowest quartile, or 0 vs. more than 0. S0433 by comparison showed numerically inferior outcomes for low HLA-DR score of 0, and more similar outcomes for higher HLA-DR scores. This result was in keeping with our original rationale for the study that vorinostat would increase surface HLA-DR expression and improve immunosurveillance, but again this was not statistically significant.
In addition to the poor outcome associated with complete loss of HLA-DR in B cell lymphomas, we recently reported on the unfavorable impact of loss from the cell surface with retained HLA-DR in cytoplasmic punctate staining pattern in DLBCL. 3 In the current study, 5 patients had no staining, 12 had cytoplasmic punctate staining, 13 had mixed punctate and surface staining, and 22 had surface only staining. As expected, patients with no staining (truly negative) had the worst 2-year PFS at 40%, while punctate had 83%, mixed punctate/surface 85%, and surface only had 64% 2-year PFS (P 5 .0627). However, 2-year OS was 80%-85% for all 4 staining patterns. Of interest, patients with negative or punctate HLA-DR pattern were 2.7 times more likely to be GCB than those with any surface HLA-DR pattern (surface/punctate or surface), but this was not statistically significant (P 5 .29). There were no associations between HLA-DR expression and IPI, MYC expression, BCL2 expression, double (MYC and BCL2) expression, Ki67, or COO.
Immunohistochemical stains for T-cell subsets and macrophages were available on 39 to 44 of phase I/II patients, depending on the This study is the largest trial combining an HDACI with chemotherapy in B-cell malignancy, where the role of this drug class remains to be defined.
Straus et al. 17 reported a trial of 29 patients with relapsed/refractory DLBCL treated with vorinostat and R-CEPP without procarbazine, with vorinostat MTD established at 300 mg po days 1-10. Febrile neutropenia rate was 17%, with median PFS of 9.2 months and OS of 17.5 months. Our study used doxorubicin instead of etoposide, but was frontline and in younger patients, and therefore toxicity was more than expected. Oki at al. 18 combined vorinostat with CHOP in 14 patients with newly diagnosed T-cell lymphomas. Three patients discontinued due to toxicity, including one with repeat neutropenic fever, one with grade 3 mucositis, and one with grade 3
anemia. We used 8 cycles of R-CHOP in our trial, which could have contributed to toxicity, and the multicenter nature of a cooperative study probably reflects the true toxicity of a regimen to a greater extent than single center studies such as mentioned above.
Studies published since the design of this trial showed only modest activity of single agent HDACI in DLBCL. 19, 20 The rationale for this study, however, was to see if HDACI could reverse the unfavorable impact of the loss of MHCII expression. We previously published the results of SWOG phase II trial with belinostat in relapsed/refractory DLBCL, where of 2 on-treatment biopsies one responding patient had increase in MHCII expression and numbers of TILs, while a patient who did not respond did not. 10 Unlike in that prior experience we could not find an association between MHCII (HLA-DR) and T-cells in this study.
Comparison to our prior frontline DLBCL study, S0433, which did not use an HDACI, 15 showed that low MCHII expressing patients have numerically inferior outcomes on that study compared to this trial.
Thus, it may indicate that addition of vorinostat, as hypothesized, did address unfavorable features of low MCHII expression. However, the difference was not statistically significant, and bore all the limitations of cross-study comparisons. Complete lack of MHCII staining on S0806
was borderline statistically significant (P 5 .0627), however there were only 5 patients in that cohort.
Cytokine profiling revealed that baseline elevated MIP-1beta concentration correlated with worse OS. MIP-1beta, also known as CCL4, is an autocrine chemokine that has been shown to a biomarker of Bcell receptor pathway and to correlate with worse outcomes in DLBCL. 21 In this study we looked at FOXP3, a marker of T-reg lineage, by immunohistochemistry, but it did not correlate with PFS.
The future of HDACI in B-cell lymphoma is hampered by lack of biomarkers predicting response and outcomes. Inactivating mutations in the genes encoding histone acetyltransferases CREBBP and EP300 were found in up to one third of DLBCL. 22, 23 In vitro data indicated greater sensitivity of CREBBP and EP300 mutants to vorinostat. 24 Assouline et al. 25 recently reported on 40 patients with relapsed/refractory/transformed DLBCL treated with panobinostat with or without rituximab.
They found 64% of patients having mutations in histone-modifying enzymes. They also found that mutations in MEF2B gene, which cooperates with CREBBP and EP300 to acetylate histones, were significantly associated with higher response. Future study will look at S0806 to identify if there is a subset, perhaps DLBCL harboring CREBBP and EP300
mutations that may benefit from addition of vorinostat. 
